

# A single-arm, open-label, pilot study evaluating the efficacy and safety of directly observed peginterferon alfa-2a with ribavirin in conjunction with a peer counsellor in patients actively using injecting drugs who have chronic hepatitis C and attend a drug and alcohol centre.

ACTRN12608000400369

---

Status	RECRUITING
Phase	Phase 4
Sponsor	Dr Joe Sasadeusz
Enrollment	50 participants

## Key Eligibility Criteria

---

### Inclusion (9)

- Informed consent
- Age = 18 years
- Serologic evidence of chronic hepatitis C infection by an anti-HCV antibody test and positive HCV PCR (Polymerase Chain Reaction) for > 6 months
- Detectable serum HCV-RNA (ribonucleic acid) at screening
- Compensated liver disease (Child-Pugh Grade A clinical classification)
- ... and 4 more (see full listing online)

### Exclusion (22)

- Frequency of injecting drug use of daily or greater
- Females who are pregnant, breastfeeding or planning a pregnancy
- Inability or unwillingness to provide informed consent or abide by the requirements of the study protocol
- Patients unwilling to use an acceptable method of birth control (defined as surgical sterility, intrauterine device, oral contraception, diaphragm or condom in association with a spermicide)
- Patients previously treated with interferon or ribavirin
- ... and 17 more (see full listing online)

## Locations (1 total)

---

Australia